Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Kala Pharmaceuticals Q3 EPS $(3.41) Misses $(2.15) Estimate

Author: Benzinga Newsdesk | November 13, 2023 09:11am
Kala Pharmaceuticals (NASDAQ:KALA) reported quarterly losses of $(3.41) per share which missed the analyst consensus estimate of $(2.15) by 58.6 percent. This is a 61.77 percent increase over losses of $(8.92) per share from the same period last year.

Posted In: KALA


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist